Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$0.86 and last traded at C$0.87, with a volume of 254159 shares traded. The stock had previously closed at C$0.93.
Analyst Ratings Changes
Separately, Raymond James upgraded Oncolytics Biotech to a "moderate buy" rating in a research note on Thursday, November 14th.
Check Out Our Latest Stock Analysis on ONC
Oncolytics Biotech Stock Performance
The company has a market cap of C$69.37 million, a price-to-earnings ratio of -2.51 and a beta of 1.35. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The stock's fifty day simple moving average is C$1.12 and its two-hundred day simple moving average is C$1.31.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
